The Structure of Phosphorylated Gsk-3Beta Complexed with a Peptide, Frattide, that Inhibits Beta-Catenin Phosphorylation
Bax, B., Carter, P.S., Lewis, C., Guy, A.R., Bridges, A., Tanner, R., Pettman, G., Mannix, C., Culbert, A.A., Brown, M.J.B., Smith, D.G., Reith, A.D.(2001) Structure 9: 1143
- PubMed: 11738041 
- DOI: https://doi.org/10.1016/s0969-2126(01)00679-7
- Primary Citation of Related Structures:  
1GNG - PubMed Abstract: 
Glycogen synthase kinase-3 (GSK-3) sequentially phosphorylates four serine residues on glycogen synthase (GS), in the sequence SxxxSxxxSxxx-SxxxS(p), by recognizing and phosphorylating the first serine in the sequence motif SxxxS(P) (where S(p) represents a phosphoserine). FRATtide (a peptide derived from a GSK-3 binding protein) binds to GSK-3 and blocks GSK-3 from interacting with Axin. This inhibits the Axin-dependent phosphorylation of beta-catenin by GSK-3.
Organizational Affiliation: 
Department of Structural Biology, GlaxoSmithKline Pharmaceuticals, Harlow, Essex CM19 5AD, United Kingdom. benjamin_d_bax@gsk.com